share_log

Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

Benzinga ·  Oct 3, 2023 11:52

Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment